title: Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.
authors.affiliation: Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy. Electronic address: francesco.gelsomino@aosp.bo.it.
authors.forename: Francesco
authors.initials: F
authors.lastname: Gelsomino
authors.affiliation: Nuclear Medicine Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Ambrosini
authors.affiliation: Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Melotti
authors.affiliation: Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Sperandi
authors.affiliation: Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ardizzoni
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D001859:Bone Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018450:Disease Progression; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D013450:Sulfones / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D011743:Pyrimidines; D013450:Sulfones; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib